Valion Bio annual r&d spending
2021
2022
2023
2024
2025
Valion Bio R&D Spending Growth & History (VBIO)
Valion Bio's r&d spending was $3.1M for fiscal 2025.
View full Valion Bio company overviewValion Bio annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.1M | $1.8M | +138.46% |
| 2024 | 2024-12-31 | $1.3M | −$342,000 | −20.66% |
| 2023 | 2023-12-31 | $1.7M | −$75,000 | −4.34% |
| 2022 | 2022-12-31 | $1.7M | $852,000 | +97.04% |
| 2021 | 2021-12-31 | $878,000 | — | — |
Valion Bio quarterly r&d spending
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.7M | $2.0M | +312.82% |
| Q1 2026 · Mar 31 | 2026-03-31 | $1.9M | $1.5M | +453.43% |
| Q1 2026 · Mar 30 | 2026-03-30 | $1.9M | $1.5M | +453.43% |
| Q4 2025 | 2025-12-31 | $1.3M | $950,000 | +285.29% |
| Q3 2025 | 2025-09-30 | $858,000 | $436,000 | +103.32% |
| Q2 2025 | 2025-06-30 | $655,000 | $353,000 | +116.89% |
| Q1 2025 | 2025-03-31 | $335,000 | $79,000 | +30.86% |
| Q4 2024 | 2024-12-31 | $333,000 | −$27,000 | −7.50% |
| Q3 2024 | 2024-09-30 | $422,000 | $85,000 | +25.22% |
| Q2 2024 | 2024-06-30 | $302,000 | −$166,000 | −35.47% |
| Q1 2024 | 2024-03-31 | $256,000 | −$234,000 | −47.76% |
| Q4 2023 | 2023-12-31 | $360,000 | −$73,000 | −16.86% |
| Q3 2023 | 2023-09-30 | $337,000 | −$62,000 | −15.54% |
| Q2 2023 | 2023-06-30 | $468,000 | −$29,000 | −5.84% |
| Q1 2023 | 2023-03-31 | $490,000 | $89,000 | +22.19% |
| Q4 2022 | 2022-12-31 | $433,000 | $120,000 | +38.34% |
| Q3 2022 | 2022-09-30 | $399,000 | $224,000 | +128.00% |
| Q2 2022 | 2022-06-30 | $497,000 | $305,000 | +158.85% |
| Q1 2022 | 2022-03-31 | $401,000 | $203,000 | +102.53% |
| Q4 2021 | 2021-12-31 | $313,000 | — | — |
| Q3 2021 | 2021-09-30 | $175,000 | — | — |
| Q2 2021 | 2021-06-30 | $192,000 | — | — |
| Q1 2021 | 2021-03-31 | $198,000 | — | — |
Valion Bio r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Valion Bio's r&d spending increased from $878,000 to $3.1M, a change of $2.3M. The latest reported quarter, Q2 2026, shows $2.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Valion Bio source filings ↗